ARPO Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (27 Aug 2021 @ 06:00):

Stats
Tagesvolumen	826 006
Durchschnittsvolumen	401 776
Marktkapitalisierung	53.67M
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.177 (8.05%)

Insider Trading

Date	Person	Action	Amount	type
2021-06-30	Dalal Anupam	Buy	7 400	Common Stock
2021-06-30	Castelein Caley	Buy	7 811	Common Stock
2021-06-30	Cohen Cheryl	Buy	8 140	Common Stock
2021-06-17	Cohen Cheryl	Buy	100 000	Stock Option (Right to Buy)
2021-03-31	Cohen Cheryl	Buy	8 020	Common Stock

INSIDER POWER
0.00
Last 63 transactions
Buy: 4 252 497 \| Sell: 3 402 072

Volumen Korrelation

Lang: 0.22 (neutral)

Kurz: 0.14 (neutral)

Signal:(54.23) Neutral

Aerpio Pharmaceuticals Korrelation

10 Am meisten positiv korreliert
RMRM	0.906
GAINL	0.889
KURA	0.84
PETZ	0.838
SEV	0.82
OGI	0.816
SVAC	0.814
THCB	0.813
TLGT	0.811
MBOT	0.808

10 Am meisten negativ korreliert
HWCC	-0.835
BIDU	-0.818
POWL	-0.811
OBAS	-0.808
RXDX	-0.806
LWAC	-0.806
FWONK	-0.806
BNIX	-0.806
BKNG	-0.804
FWONA	-0.803

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Aerpio Pharmaceuticals Korrelation - Währung/Rohstoff

-0.42
( neutral )

0.41
( neutral )

0.00
( neutral )

-0.05
( neutral )

-0.31
( neutral )

0.47
( neutral )

Aerpio Pharmaceuticals Finanzdaten

Annual	2022
Umsatz:	$5.51M
Bruttogewinn:	$-29.51M (-535.75 %)
EPS:	$-1.080

FY	2022
Umsatz:	$5.51M
Bruttogewinn:	$-29.51M (-535.75 %)
EPS:	$-1.080

Financial Reports:

No articles found.

Aerpio Pharmaceuticals

Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees. The firm is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.